TW202346573A - 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 - Google Patents
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 Download PDFInfo
- Publication number
- TW202346573A TW202346573A TW112103170A TW112103170A TW202346573A TW 202346573 A TW202346573 A TW 202346573A TW 112103170 A TW112103170 A TW 112103170A TW 112103170 A TW112103170 A TW 112103170A TW 202346573 A TW202346573 A TW 202346573A
- Authority
- TW
- Taiwan
- Prior art keywords
- til
- population
- til population
- days
- expansion
- Prior art date
Links
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 title claims abstract description 869
- 238000000034 method Methods 0.000 title claims abstract description 403
- 239000000203 mixture Substances 0.000 title claims abstract description 113
- 102000004127 Cytokines Human genes 0.000 title abstract description 3
- 108090000695 Cytokines Proteins 0.000 title abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 245
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 213
- 210000004027 cell Anatomy 0.000 claims abstract description 93
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 102000000588 Interleukin-2 Human genes 0.000 claims description 260
- 108010002350 Interleukin-2 Proteins 0.000 claims description 260
- 102000037865 fusion proteins Human genes 0.000 claims description 155
- 108020001507 fusion proteins Proteins 0.000 claims description 155
- 230000003321 amplification Effects 0.000 claims description 140
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 140
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 137
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 128
- 239000006143 cell culture medium Substances 0.000 claims description 125
- 102000003812 Interleukin-15 Human genes 0.000 claims description 108
- 108090000172 Interleukin-15 Proteins 0.000 claims description 108
- 239000012634 fragment Substances 0.000 claims description 95
- 102000015696 Interleukins Human genes 0.000 claims description 91
- 108010063738 Interleukins Proteins 0.000 claims description 91
- 108010074108 interleukin-21 Proteins 0.000 claims description 84
- 102100030704 Interleukin-21 Human genes 0.000 claims description 83
- 230000027455 binding Effects 0.000 claims description 78
- -1 IFNγ Proteins 0.000 claims description 72
- 230000001225 therapeutic effect Effects 0.000 claims description 70
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 69
- 241000282414 Homo sapiens Species 0.000 claims description 67
- 239000002955 immunomodulating agent Substances 0.000 claims description 63
- 229940121354 immunomodulator Drugs 0.000 claims description 63
- 201000011510 cancer Diseases 0.000 claims description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 229940047122 interleukins Drugs 0.000 claims description 58
- 238000001802 infusion Methods 0.000 claims description 56
- 238000012258 culturing Methods 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 210000000170 cell membrane Anatomy 0.000 claims description 52
- 239000012528 membrane Substances 0.000 claims description 49
- 150000007523 nucleic acids Chemical class 0.000 claims description 49
- 239000000427 antigen Substances 0.000 claims description 48
- 102000036639 antigens Human genes 0.000 claims description 48
- 108091007433 antigens Proteins 0.000 claims description 48
- 238000012546 transfer Methods 0.000 claims description 48
- 102000003810 Interleukin-18 Human genes 0.000 claims description 47
- 108090000171 Interleukin-18 Proteins 0.000 claims description 47
- 238000001574 biopsy Methods 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 45
- 108020004707 nucleic acids Proteins 0.000 claims description 44
- 108010002586 Interleukin-7 Proteins 0.000 claims description 35
- 229960000106 biosimilars Drugs 0.000 claims description 35
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 230000007704 transition Effects 0.000 claims description 32
- 230000000977 initiatory effect Effects 0.000 claims description 31
- 230000004048 modification Effects 0.000 claims description 28
- 238000012986 modification Methods 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 28
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 23
- 230000002584 immunomodulator Effects 0.000 claims description 23
- 229940123189 CD40 agonist Drugs 0.000 claims description 22
- 102000000704 Interleukin-7 Human genes 0.000 claims description 22
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 21
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 21
- 238000013188 needle biopsy Methods 0.000 claims description 21
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 19
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 19
- 108090001005 Interleukin-6 Proteins 0.000 claims description 19
- 102000004889 Interleukin-6 Human genes 0.000 claims description 19
- 108010002335 Interleukin-9 Proteins 0.000 claims description 19
- 102000000585 Interleukin-9 Human genes 0.000 claims description 19
- 108700012920 TNF Proteins 0.000 claims description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 19
- 108010029697 CD40 Ligand Proteins 0.000 claims description 18
- 102100032937 CD40 ligand Human genes 0.000 claims description 18
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 18
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 claims description 18
- 102000056003 human IL15 Human genes 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 18
- 238000002271 resection Methods 0.000 claims description 18
- 230000001502 supplementing effect Effects 0.000 claims description 18
- 101150013553 CD40 gene Proteins 0.000 claims description 17
- 102000004388 Interleukin-4 Human genes 0.000 claims description 17
- 108090000978 Interleukin-4 Proteins 0.000 claims description 17
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 17
- 238000012239 gene modification Methods 0.000 claims description 17
- 239000002105 nanoparticle Substances 0.000 claims description 17
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 17
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 16
- 210000004698 lymphocyte Anatomy 0.000 claims description 16
- 230000009466 transformation Effects 0.000 claims description 16
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 15
- 108010066979 Interleukin-27 Proteins 0.000 claims description 15
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims description 15
- 238000012545 processing Methods 0.000 claims description 15
- 238000002560 therapeutic procedure Methods 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 14
- 230000005017 genetic modification Effects 0.000 claims description 14
- 235000013617 genetically modified food Nutrition 0.000 claims description 14
- 108010065637 Interleukin-23 Proteins 0.000 claims description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 13
- 239000001963 growth medium Substances 0.000 claims description 12
- 230000001400 myeloablative effect Effects 0.000 claims description 12
- 229960000390 fludarabine Drugs 0.000 claims description 11
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 10
- 108700025316 aldesleukin Proteins 0.000 claims description 10
- 229960005310 aldesleukin Drugs 0.000 claims description 10
- 229960004397 cyclophosphamide Drugs 0.000 claims description 10
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 9
- 238000005138 cryopreservation Methods 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 230000001177 retroviral effect Effects 0.000 claims description 9
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 8
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 claims description 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 8
- 102000043959 human IL18 Human genes 0.000 claims description 8
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 7
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 7
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 229940122738 CD3 agonist Drugs 0.000 claims description 6
- 108091033409 CRISPR Proteins 0.000 claims description 6
- 102100027377 HBS1-like protein Human genes 0.000 claims description 6
- 101001009070 Homo sapiens HBS1-like protein Proteins 0.000 claims description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 238000004520 electroporation Methods 0.000 claims description 6
- 210000005259 peripheral blood Anatomy 0.000 claims description 6
- 239000011886 peripheral blood Substances 0.000 claims description 6
- 238000001890 transfection Methods 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 101150043532 CISH gene Proteins 0.000 claims description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 5
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 5
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 5
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 5
- 102000017578 LAG3 Human genes 0.000 claims description 5
- 101150030213 Lag3 gene Proteins 0.000 claims description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 210000000265 leukocyte Anatomy 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 239000004055 small Interfering RNA Substances 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 4
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 claims description 4
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 4
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 claims description 4
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 4
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
- 101001050476 Homo sapiens Tyrosine-protein kinase ITK/TSK Proteins 0.000 claims description 4
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 4
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 claims description 4
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 claims description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 229960001507 ibrutinib Drugs 0.000 claims description 4
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 claims description 3
- 102100034614 Ankyrin repeat domain-containing protein 11 Human genes 0.000 claims description 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 3
- 102100021247 BCL-6 corepressor Human genes 0.000 claims description 3
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 claims description 3
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims description 3
- 102100024263 CD160 antigen Human genes 0.000 claims description 3
- 108090000397 Caspase 3 Proteins 0.000 claims description 3
- 102100026549 Caspase-10 Human genes 0.000 claims description 3
- 102100029855 Caspase-3 Human genes 0.000 claims description 3
- 102100038918 Caspase-6 Human genes 0.000 claims description 3
- 102100038902 Caspase-7 Human genes 0.000 claims description 3
- 102100026548 Caspase-8 Human genes 0.000 claims description 3
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims description 3
- 101000809594 Escherichia coli (strain K12) Shikimate kinase 1 Proteins 0.000 claims description 3
- 102100026693 FAS-associated death domain protein Human genes 0.000 claims description 3
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 3
- 102100040754 Guanylate cyclase soluble subunit alpha-1 Human genes 0.000 claims description 3
- 102100040735 Guanylate cyclase soluble subunit alpha-2 Human genes 0.000 claims description 3
- 102100040739 Guanylate cyclase soluble subunit beta-1 Human genes 0.000 claims description 3
- 102100028963 Guanylate cyclase soluble subunit beta-2 Human genes 0.000 claims description 3
- 102100028008 Heme oxygenase 2 Human genes 0.000 claims description 3
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 claims description 3
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims description 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 3
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 claims description 3
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 3
- 101000983518 Homo sapiens Caspase-10 Proteins 0.000 claims description 3
- 101000741087 Homo sapiens Caspase-6 Proteins 0.000 claims description 3
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 claims description 3
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 claims description 3
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 claims description 3
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 3
- 101001038755 Homo sapiens Guanylate cyclase soluble subunit alpha-1 Proteins 0.000 claims description 3
- 101001038749 Homo sapiens Guanylate cyclase soluble subunit alpha-2 Proteins 0.000 claims description 3
- 101001038731 Homo sapiens Guanylate cyclase soluble subunit beta-1 Proteins 0.000 claims description 3
- 101001059095 Homo sapiens Guanylate cyclase soluble subunit beta-2 Proteins 0.000 claims description 3
- 101001079615 Homo sapiens Heme oxygenase 2 Proteins 0.000 claims description 3
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 claims description 3
- 101001083151 Homo sapiens Interleukin-10 receptor subunit alpha Proteins 0.000 claims description 3
- 101001003149 Homo sapiens Interleukin-10 receptor subunit beta Proteins 0.000 claims description 3
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 3
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 claims description 3
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 3
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims description 3
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 3
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 claims description 3
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims description 3
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 claims description 3
- 101001068019 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Proteins 0.000 claims description 3
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 3
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 3
- 101000688930 Homo sapiens Signaling threshold-regulating transmembrane adapter 1 Proteins 0.000 claims description 3
- 101000863692 Homo sapiens Ski oncogene Proteins 0.000 claims description 3
- 101000688996 Homo sapiens Ski-like protein Proteins 0.000 claims description 3
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 claims description 3
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 3
- 101000648265 Homo sapiens Thymocyte selection-associated high mobility group box protein TOX Proteins 0.000 claims description 3
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 3
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 claims description 3
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 claims description 3
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 3
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 claims description 3
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 3
- 101710123016 Integrin alpha-L Proteins 0.000 claims description 3
- 102000003814 Interleukin-10 Human genes 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 claims description 3
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 claims description 3
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 3
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 claims description 3
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 3
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims description 3
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 3
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 3
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims description 3
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims description 3
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims description 3
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims description 3
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 3
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims description 3
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 claims description 3
- 102100034470 Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Human genes 0.000 claims description 3
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 3
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 3
- 102100024453 Signaling threshold-regulating transmembrane adapter 1 Human genes 0.000 claims description 3
- 102100029969 Ski oncogene Human genes 0.000 claims description 3
- 102100024451 Ski-like protein Human genes 0.000 claims description 3
- 101150045565 Socs1 gene Proteins 0.000 claims description 3
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims description 3
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims description 3
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 claims description 3
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 claims description 3
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 3
- 108091007178 TNFRSF10A Proteins 0.000 claims description 3
- 102100028788 Thymocyte selection-associated high mobility group box protein TOX Human genes 0.000 claims description 3
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 3
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 3
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 claims description 3
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 claims description 3
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 3
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims description 3
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims description 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims description 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 claims description 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims description 2
- 101001018021 Homo sapiens T-lymphocyte surface antigen Ly-9 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 2
- RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 claims description 2
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 claims description 2
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 claims description 2
- 101800001731 Notch 2 intracellular domain Proteins 0.000 claims description 2
- 102400000545 Notch 2 intracellular domain Human genes 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 102100029216 SLAM family member 5 Human genes 0.000 claims description 2
- 102100033447 T-lymphocyte surface antigen Ly-9 Human genes 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 229920006317 cationic polymer Polymers 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000030279 gene silencing Effects 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 229960004635 mesna Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 32
- 108010065805 Interleukin-12 Proteins 0.000 claims 32
- 238000010354 CRISPR gene editing Methods 0.000 claims 4
- 102100030703 Interleukin-22 Human genes 0.000 claims 3
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 1
- 101000924476 Homo sapiens Ankyrin repeat domain-containing protein 11 Proteins 0.000 claims 1
- 101100165236 Homo sapiens BCOR gene Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 7
- 230000004083 survival effect Effects 0.000 abstract description 7
- 230000003308 immunostimulating effect Effects 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 4
- 238000011275 oncology therapy Methods 0.000 abstract description 3
- 125000005647 linker group Chemical group 0.000 description 78
- 235000018102 proteins Nutrition 0.000 description 52
- 108090000765 processed proteins & peptides Proteins 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 36
- 210000004379 membrane Anatomy 0.000 description 27
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 26
- 239000000523 sample Substances 0.000 description 26
- 239000002202 Polyethylene glycol Substances 0.000 description 23
- 229920001223 polyethylene glycol Polymers 0.000 description 23
- 238000006467 substitution reaction Methods 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 108060003951 Immunoglobulin Proteins 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 102000018358 immunoglobulin Human genes 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000002253 acid Substances 0.000 description 14
- 230000001640 apoptogenic effect Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 230000013595 glycosylation Effects 0.000 description 14
- 238000006206 glycosylation reaction Methods 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 229920002477 rna polymer Polymers 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 229940126601 medicinal product Drugs 0.000 description 12
- 210000003071 memory t lymphocyte Anatomy 0.000 description 12
- 239000000562 conjugate Substances 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 108020005176 AU Rich Elements Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 210000004602 germ cell Anatomy 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 229920003169 water-soluble polymer Polymers 0.000 description 8
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 7
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 7
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 7
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229960002317 succinimide Drugs 0.000 description 7
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 102000013264 Interleukin-23 Human genes 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 102000055277 human IL2 Human genes 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 5
- 238000002659 cell therapy Methods 0.000 description 5
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 229910052720 vanadium Inorganic materials 0.000 description 5
- 108090000663 Annexin A1 Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102100034235 ELAV-like protein 1 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000006320 pegylation Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 102100034980 ICOS ligand Human genes 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 3
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 3
- OJYRJTUKEXSKOS-ZETCQYMHSA-N N[C@@H](CCCCNOCCN=[N+]=[N-])C(O)=O Chemical compound N[C@@H](CCCCNOCCN=[N+]=[N-])C(O)=O OJYRJTUKEXSKOS-ZETCQYMHSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 210000004241 Th2 cell Anatomy 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000013475 authorization Methods 0.000 description 3
- 229940121413 bempegaldesleukin Drugs 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012595 freezing medium Substances 0.000 description 3
- 238000003144 genetic modification method Methods 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 2
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 2
- RBAFCMJBDZWZIV-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-azido-2-hydroxybenzoate Chemical compound OC1=CC(N=[N+]=[N-])=CC=C1C(=O)ON1C(=O)CCC1=O RBAFCMJBDZWZIV-UHFFFAOYSA-N 0.000 description 2
- LWAVGNJLLQSNNN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-azidobenzoate Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C(=O)ON1C(=O)CCC1=O LWAVGNJLLQSNNN-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GAJBPZXIKZXTCG-VIFPVBQESA-N (2s)-2-amino-3-[4-(azidomethyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(CN=[N+]=[N-])C=C1 GAJBPZXIKZXTCG-VIFPVBQESA-N 0.000 description 2
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 2
- GERXSZLDSOPHJV-UHFFFAOYSA-N (4-nitrophenyl) 2-iodoacetate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)CI)C=C1 GERXSZLDSOPHJV-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- AASYSXRGODIQGY-UHFFFAOYSA-N 1-[1-(2,5-dioxopyrrol-1-yl)hexyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(CCCCC)N1C(=O)C=CC1=O AASYSXRGODIQGY-UHFFFAOYSA-N 0.000 description 2
- CALIYGMVBZRBLV-UHFFFAOYSA-N 2-(4-azidophenyl)-2-oxoacetaldehyde Chemical compound [N-]=[N+]=NC1=CC=C(C(=O)C=O)C=C1 CALIYGMVBZRBLV-UHFFFAOYSA-N 0.000 description 2
- YHJZWYNRTYKWEC-UHFFFAOYSA-N 2-diazonio-3,3,3-trifluoro-1-(4-nitrophenoxy)prop-1-en-1-olate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)C(=[N+]=[N-])C(F)(F)F)C=C1 YHJZWYNRTYKWEC-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- DJBRKGZFUXKLKO-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSC1=CC=CC=N1 DJBRKGZFUXKLKO-UHFFFAOYSA-N 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 2
- 101710188804 Ankyrin repeat domain-containing protein 11 Proteins 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 2
- 108091007045 Cullin Ring E3 Ligases Proteins 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 description 2
- 108010019236 Fucosyltransferases Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000894690 Homo sapiens BCL-6 corepressor Proteins 0.000 description 2
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 2
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 2
- 108700031757 NKTR-214 Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 240000007019 Oxalis corniculata Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 2
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003690 classically activated macrophage Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 2
- 101150023212 fut8 gene Proteins 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 102000052622 human IL7 Human genes 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 2
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- FUOJEDZPVVDXHI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-azido-2-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC=C(N=[N+]=[N-])C=C1C(=O)ON1C(=O)CCC1=O FUOJEDZPVVDXHI-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- YYTDJPUFAVPHQA-VKHMYHEASA-N (2s)-2-amino-3-(2,3,4,5,6-pentafluorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(F)C(F)=C(F)C(F)=C1F YYTDJPUFAVPHQA-VKHMYHEASA-N 0.000 description 1
- PEMUHKUIQHFMTH-QMMMGPOBSA-N (2s)-2-amino-3-(4-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-QMMMGPOBSA-N 0.000 description 1
- JSXMFBNJRFXRCX-NSHDSACASA-N (2s)-2-amino-3-(4-prop-2-ynoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OCC#C)C=C1 JSXMFBNJRFXRCX-NSHDSACASA-N 0.000 description 1
- BJOQKIKXKGJLIJ-NSHDSACASA-N (2s)-2-amino-3-(4-prop-2-ynylphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(CC#C)C=C1 BJOQKIKXKGJLIJ-NSHDSACASA-N 0.000 description 1
- NEMHIKRLROONTL-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-azidophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-QMMMGPOBSA-N 0.000 description 1
- ZXSBHXZKWRIEIA-JTQLQIEISA-N (2s)-3-(4-acetylphenyl)-2-azaniumylpropanoate Chemical compound CC(=O)C1=CC=C(C[C@H](N)C(O)=O)C=C1 ZXSBHXZKWRIEIA-JTQLQIEISA-N 0.000 description 1
- VOTJUWBJENROFB-UHFFFAOYSA-N 1-[3-[[3-(2,5-dioxo-3-sulfopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VOTJUWBJENROFB-UHFFFAOYSA-N 0.000 description 1
- VCRPKWLNHWPCSR-UHFFFAOYSA-N 1-diazonio-3-(4-nitrophenoxy)-3-oxoprop-1-en-2-olate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)C(=O)C=[N+]=[N-])C=C1 VCRPKWLNHWPCSR-UHFFFAOYSA-N 0.000 description 1
- KHAWDEWNXJIVCJ-UHFFFAOYSA-N 1-fluoro-4-(4-fluoro-3-nitrophenyl)sulfonyl-2-nitrobenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC(S(=O)(=O)C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 KHAWDEWNXJIVCJ-UHFFFAOYSA-N 0.000 description 1
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
- ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
- JDEYYCJOIRKTCS-UHFFFAOYSA-N 2,5-dioxopyrrolidine-3-sulfonic acid;octanedioic acid Chemical compound OS(=O)(=O)C1CC(=O)NC1=O.OS(=O)(=O)C1CC(=O)NC1=O.OC(=O)CCCCCCC(O)=O JDEYYCJOIRKTCS-UHFFFAOYSA-N 0.000 description 1
- GGBIMBICBVPVDL-UHFFFAOYSA-N 2-(propyldisulfanyl)pyridine Chemical compound CCCSSC1=CC=CC=N1 GGBIMBICBVPVDL-UHFFFAOYSA-N 0.000 description 1
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- YVYRKTXQJJKRJG-UHFFFAOYSA-N 2-iodo-n-[6-[(2-iodoacetyl)amino]hexyl]acetamide Chemical compound ICC(=O)NCCCCCCNC(=O)CI YVYRKTXQJJKRJG-UHFFFAOYSA-N 0.000 description 1
- WBGKAOURNYRYBT-UHFFFAOYSA-N 2-sulfopropanoic acid Chemical compound OC(=O)C(C)S(O)(=O)=O WBGKAOURNYRYBT-UHFFFAOYSA-N 0.000 description 1
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
- JMUAKWNHKQBPGJ-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)-n-[4-[3-(pyridin-2-yldisulfanyl)propanoylamino]butyl]propanamide Chemical compound C=1C=CC=NC=1SSCCC(=O)NCCCCNC(=O)CCSSC1=CC=CC=N1 JMUAKWNHKQBPGJ-UHFFFAOYSA-N 0.000 description 1
- NITXODYAMWZEJY-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanehydrazide Chemical compound NNC(=O)CCSSC1=CC=CC=N1 NITXODYAMWZEJY-UHFFFAOYSA-N 0.000 description 1
- OEOCGLHNKJKVBF-UHFFFAOYSA-N 3-benzyl-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1N(O)C(=O)CC1CC1=CC=CC=C1 OEOCGLHNKJKVBF-UHFFFAOYSA-N 0.000 description 1
- JZRBSTONIYRNRI-VIFPVBQESA-N 3-methylphenylalanine Chemical compound CC1=CC=CC(C[C@H](N)C(O)=O)=C1 JZRBSTONIYRNRI-VIFPVBQESA-N 0.000 description 1
- IRZQDMYEJPNDEN-UHFFFAOYSA-N 3-phenyl-2-aminobutanoic acid Natural products OC(=O)C(N)C(C)C1=CC=CC=C1 IRZQDMYEJPNDEN-UHFFFAOYSA-N 0.000 description 1
- LAEUQSVCOOXLEE-UHFFFAOYSA-N 4-[(2-iodoacetyl)amino]benzoic acid Chemical compound OC(=O)C1=CC=C(NC(=O)CI)C=C1 LAEUQSVCOOXLEE-UHFFFAOYSA-N 0.000 description 1
- ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- YRLKXQVDEQEYSN-UHFFFAOYSA-N 4-azidobenzohydrazide Chemical compound NNC(=O)C1=CC=C(N=[N+]=[N-])C=C1 YRLKXQVDEQEYSN-UHFFFAOYSA-N 0.000 description 1
- PZNQZSRPDOEBMS-QMMMGPOBSA-N 4-iodo-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(I)C=C1 PZNQZSRPDOEBMS-QMMMGPOBSA-N 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 108091007504 ADAM10 Proteins 0.000 description 1
- 108091007507 ADAM12 Proteins 0.000 description 1
- 102000029750 ADAMTS Human genes 0.000 description 1
- 108091022879 ADAMTS Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101710146120 Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- GPBFJOJPPZBEEX-UHFFFAOYSA-N C(=O)(O)C(O)C(O)C(=O)O.S(=O)(=O)(O)C1C(C(=O)NC1=O)S(=O)(=O)O Chemical compound C(=O)(O)C(O)C(O)C(=O)O.S(=O)(=O)(O)C1C(C(=O)NC1=O)S(=O)(=O)O GPBFJOJPPZBEEX-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150077194 CAP1 gene Proteins 0.000 description 1
- 101150014715 CAP2 gene Proteins 0.000 description 1
- 108010059108 CD18 Antigens Proteins 0.000 description 1
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 108090000613 Cathepsin S Proteins 0.000 description 1
- 102100035654 Cathepsin S Human genes 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102220473613 Cytochrome b5_R67A_mutation Human genes 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 description 1
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 description 1
- 102000016662 ELAV Proteins Human genes 0.000 description 1
- 108010053101 ELAV Proteins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000214054 Equine rhinitis A virus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000872170 Homo sapiens Polycomb complex protein BMI-1 Proteins 0.000 description 1
- 101000687438 Homo sapiens Prolactin Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- NRSPOJRMDVHRCX-UHFFFAOYSA-N IC=1C(C(C=CC1C)(C)S(=O)(=O)O)I Chemical compound IC=1C(C(C=CC1C)(C)S(=O)(=O)O)I NRSPOJRMDVHRCX-UHFFFAOYSA-N 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102100032970 Myogenin Human genes 0.000 description 1
- 108010056785 Myogenin Proteins 0.000 description 1
- ABQAYNZTNCGVRM-UHFFFAOYSA-N N(=[N+]=[N-])C1=CC=C(C(=O)O)C=C1.ON1C(C(CC1=O)S(=O)(=O)O)=O Chemical compound N(=[N+]=[N-])C1=CC=C(C(=O)O)C=C1.ON1C(C(CC1=O)S(=O)(=O)O)=O ABQAYNZTNCGVRM-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 101100438378 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-1 gene Proteins 0.000 description 1
- 101100326803 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-2 gene Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000017954 Nuclear factor of activated T cells (NFAT) Human genes 0.000 description 1
- 108050007058 Nuclear factor of activated T cells (NFAT) Proteins 0.000 description 1
- GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical group NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 1
- 229920001389 Poly(hydroxyalkylmethacrylamide) Polymers 0.000 description 1
- 102100033566 Polycomb complex protein BMI-1 Human genes 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 101710180319 Protease 1 Proteins 0.000 description 1
- 101710180316 Protease 2 Proteins 0.000 description 1
- 101710180313 Protease 3 Proteins 0.000 description 1
- 101710180309 Protease 4 Proteins 0.000 description 1
- 101710180012 Protease 7 Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000009190 Transthyretin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 1
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 1
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- PZAGQUOSOTUKEC-UHFFFAOYSA-N acetic acid;sulfuric acid Chemical compound CC(O)=O.OS(O)(=O)=O PZAGQUOSOTUKEC-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 239000012969 di-tertiary-butyl peroxide Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ODTZGFFHYPHJNS-UHFFFAOYSA-N n-(4-benzoylphenyl)-2-iodoacetamide Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)C1=CC=CC=C1 ODTZGFFHYPHJNS-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001390 poly(hydroxyalkylmethacrylate) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- DXGIRFAFSFKYCF-UHFFFAOYSA-N propanehydrazide Chemical compound CCC(=O)NN DXGIRFAFSFKYCF-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910000058 selane Inorganic materials 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950010127 teplizumab Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4234—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263304498P | 2022-01-28 | 2022-01-28 | |
| US63/304,498 | 2022-01-28 | ||
| US202263356933P | 2022-06-29 | 2022-06-29 | |
| US63/356,933 | 2022-06-29 | ||
| US202263394267P | 2022-08-01 | 2022-08-01 | |
| US63/394,267 | 2022-08-01 | ||
| US202263382493P | 2022-11-04 | 2022-11-04 | |
| US63/382,493 | 2022-11-04 | ||
| US202263429114P | 2022-11-30 | 2022-11-30 | |
| US63/429,114 | 2022-11-30 | ||
| WOPCT/US23/61474 | 2023-01-27 | ||
| PCT/US2023/061474 WO2023147488A1 (en) | 2022-01-28 | 2023-01-27 | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202346573A true TW202346573A (zh) | 2023-12-01 |
Family
ID=85410360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112103170A TW202346573A (zh) | 2022-01-28 | 2023-01-30 | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250099588A1 (enExample) |
| EP (1) | EP4469065A1 (enExample) |
| JP (1) | JP2025504908A (enExample) |
| CA (1) | CA3243419A1 (enExample) |
| TW (1) | TW202346573A (enExample) |
| WO (1) | WO2023147488A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025054540A1 (en) * | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗fap-light融合蛋白及其用途 |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5128257A (en) | 1987-08-31 | 1992-07-07 | Baer Bradford W | Electroporation apparatus and process |
| DE68925030T2 (de) | 1988-01-21 | 1996-07-25 | Massachusetts Inst Technology | Molekültransport durch gewebe mit der verwendung von elektroporation. |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| CA2019758C (en) | 1990-06-25 | 2001-09-04 | Kevin L. Firth | Improved electroporation device and method |
| US5137817A (en) | 1990-10-05 | 1992-08-11 | Amoco Corporation | Apparatus and method for electroporation |
| US5173158A (en) | 1991-07-22 | 1992-12-22 | Schmukler Robert E | Apparatus and methods for electroporation and electrofusion |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5304120A (en) | 1992-07-01 | 1994-04-19 | Btx Inc. | Electroporation method and apparatus for insertion of drugs and genes into endothelial cells |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5318514A (en) | 1992-08-17 | 1994-06-07 | Btx, Inc. | Applicator for the electroporation of drugs and genes into surface cells |
| GB9317380D0 (en) | 1993-08-20 | 1993-10-06 | Therexsys Ltd | Transfection process |
| US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
| JPH11505505A (ja) | 1994-06-27 | 1999-05-21 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ターゲッティングされた遺伝子輸送システム |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| DE69738522T2 (de) | 1996-08-02 | 2009-04-02 | Bristol-Myers Squibb Co. | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ATE466948T1 (de) | 1997-03-11 | 2010-05-15 | Univ Minnesota | Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle |
| US6475994B2 (en) | 1998-01-07 | 2002-11-05 | Donald A. Tomalia | Method and articles for transfection of genetic material |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK1234031T3 (en) | 1999-11-30 | 2017-07-03 | Mayo Foundation | B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| DE10120829A1 (de) | 2000-04-27 | 2001-12-20 | Max Delbrueck Centrum | Sleeping Beauty, ein Transposonvektor mit breitem Wirtsbereich für die genetische Transformation bei Wirbeltieren |
| US6627442B1 (en) | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
| CN1507357A (zh) | 2000-10-31 | 2004-06-23 | PRҩƷ����˾ | 提高生物活性分子传递的方法和组合物 |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| ES2377318T3 (es) | 2002-09-06 | 2012-03-26 | Cerulean Pharma Inc. | Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| DK1562972T3 (da) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| SI1706424T1 (sl) | 2004-01-12 | 2010-01-29 | Applied Molecular Evolution | Variante fc regij |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| AU2005331864A1 (en) | 2005-05-14 | 2006-11-23 | Fudan University | Piggybac as a tool for genetic manipulation and analysis in vertebrates |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP2160461B1 (en) | 2007-07-04 | 2012-08-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| WO2009032954A1 (en) | 2007-09-04 | 2009-03-12 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| US9283184B2 (en) | 2008-11-24 | 2016-03-15 | Massachusetts Institute Of Technology | Methods and compositions for localized agent delivery |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2010085699A2 (en) | 2009-01-23 | 2010-07-29 | The Johns Hopkins University | Mammalian piggybac transposon and methods of use |
| EP2401376A4 (en) | 2009-02-25 | 2012-11-28 | Univ Johns Hopkins | TRANSPOSON PIGGYBAC VARIANTS AND METHODS OF USE |
| US8399643B2 (en) | 2009-02-26 | 2013-03-19 | Transposagen Biopharmaceuticals, Inc. | Nucleic acids encoding hyperactive PiggyBac transposases |
| WO2010126766A1 (en) | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| AU2011265733B2 (en) | 2010-06-14 | 2014-04-17 | Iowa State University Research Foundation, Inc. | Nuclease activity of TAL effector and Foki fusion protein |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
| CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン,エルエルシー | B7−h1およびpd−1に結合する抗体およびその他の分子 |
| ES2709654T3 (es) | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| PT2768942T (pt) | 2011-10-17 | 2020-01-21 | Massachusetts Inst Technology | Entrega intracelular |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| BR112014029417B1 (pt) | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| WO2013182910A2 (en) | 2012-06-05 | 2013-12-12 | Cellectis | New transcription activator-like effector (tale) fusion protein |
| US9156897B2 (en) | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| IL239344B2 (en) | 2012-12-12 | 2024-06-01 | Broad Inst Inc | Systems engineering, methods and optimal guiding components for sequence manipulation |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| EP2840140B2 (en) | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| EP3004339B1 (en) | 2013-05-29 | 2021-07-07 | Cellectis | New compact scaffold of cas9 in the type ii crispr system |
| EP3019618B1 (en) | 2013-07-12 | 2018-10-31 | University of South Alabama | Minimal piggybac vectors for genome integration |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| CA3191031A1 (en) | 2013-09-27 | 2015-04-02 | Massachusetts Institute Of Technology | Carrier-free biologically-active protein nanostructures |
| EP3690044B1 (en) | 2014-02-11 | 2024-01-10 | The Regents of the University of Colorado, a body corporate | Crispr enabled multiplexed genome engineering |
| JP6681837B2 (ja) | 2014-03-11 | 2020-04-15 | セレクティスCellectis | 同種移植に適合するt細胞を作製するための方法 |
| US10344285B2 (en) | 2014-04-09 | 2019-07-09 | Dna2.0, Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| AU2016289530B2 (en) | 2015-07-09 | 2021-05-06 | Massachusetts Institute Of Technology | Delivery of materials to anucleate cells |
| EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| CN120842296A (zh) | 2015-09-21 | 2025-10-28 | 垂林克生物技术有限公司 | 用于合成5’-加帽rna的组合物和方法 |
| JP7033535B2 (ja) | 2016-01-12 | 2022-03-10 | スクイーズ バイオテクノロジーズ カンパニー | 複合体の細胞内送達 |
| WO2017155937A1 (en) | 2016-03-07 | 2017-09-14 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| HUE066460T2 (hu) | 2016-10-26 | 2024-08-28 | Iovance Biotherapeutics Inc | A kriokonzervált tumor infiltráló limfociták restimulációja |
| KR20190105568A (ko) | 2016-11-10 | 2019-09-17 | 넥타르 테라퓨틱스 | 종양의 면역 요법적 치료 방법 |
| MX2019007963A (es) | 2017-01-06 | 2019-10-21 | Iovance Biotherapeutics Inc | Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf. |
| KR102619747B1 (ko) | 2017-01-10 | 2023-12-29 | 넥타르 테라퓨틱스 | Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법 |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| MY206158A (en) | 2017-05-24 | 2024-12-02 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| JP2020530280A (ja) | 2017-07-03 | 2020-10-22 | トルク セラピューティクス, インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| WO2019046815A1 (en) | 2017-08-31 | 2019-03-07 | Poseida Therapeutics, Inc. | TRANSPOSON SYSTEM AND METHODS OF USE |
| WO2019136459A1 (en) * | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| EP3749770B9 (en) | 2018-02-09 | 2025-12-17 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Tethered interleukin-15 and interleukin-21 |
| WO2019210131A1 (en) * | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CA3123392A1 (en) * | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| SG11202110810WA (en) | 2019-03-29 | 2021-10-28 | Torque Therapeutics Inc | Immunotherapeutic compositions and use thereof |
| US20210038684A1 (en) | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
| EP4048295A1 (en) * | 2019-10-25 | 2022-08-31 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CN113584083A (zh) | 2020-04-30 | 2021-11-02 | 深圳市深研生物科技有限公司 | 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法 |
| CN113699146B (zh) | 2020-05-22 | 2024-07-02 | 深圳市深研生物科技有限公司 | 启动元件及包含其的逆转录病毒基因组转录盒和载体 |
| CN113699147B (zh) | 2020-05-22 | 2023-06-09 | 深圳市深研生物科技有限公司 | 基于四环素和Cumate的共调控序列 |
| JP2023550545A (ja) | 2020-11-02 | 2023-12-01 | シムハ・アイエル-18・インコーポレイテッド | インターロイキン-18バリアントおよび使用の方法 |
-
2023
- 2023-01-27 EP EP23708111.2A patent/EP4469065A1/en active Pending
- 2023-01-27 US US18/832,493 patent/US20250099588A1/en active Pending
- 2023-01-27 CA CA3243419A patent/CA3243419A1/en active Pending
- 2023-01-27 JP JP2024544388A patent/JP2025504908A/ja active Pending
- 2023-01-27 WO PCT/US2023/061474 patent/WO2023147488A1/en not_active Ceased
- 2023-01-30 TW TW112103170A patent/TW202346573A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025504908A (ja) | 2025-02-19 |
| EP4469065A1 (en) | 2024-12-04 |
| US20250099588A1 (en) | 2025-03-27 |
| WO2023147488A1 (en) | 2023-08-03 |
| CA3243419A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202241508A (zh) | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 | |
| TW202241468A (zh) | 用腫瘤浸潤性淋巴球療法與braf抑制劑及/或mek抑制劑組合治療癌症患者 | |
| TW202327631A (zh) | 利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者 | |
| TW202304480A (zh) | 腫瘤浸潤淋巴球(til)中之與cd39/cd69選擇及基因剔除相關之til擴增之方法 | |
| TW202346573A (zh) | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 | |
| TW202239415A (zh) | 腫瘤浸潤性淋巴球療法與ctla-4及pd-1抑制劑組合之治療 | |
| JP2024519029A (ja) | Pd-1遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用 | |
| TW202328439A (zh) | 使用pd-1 talen基因減弱生成til產物之方法 | |
| WO2023196877A1 (en) | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies | |
| TW202300014A (zh) | 腫瘤儲存及細胞培養組成物 | |
| WO2023147486A1 (en) | Tumor infiltrating lymphocytes engineered to express payloads | |
| TW202305360A (zh) | 用於t細胞共培養效力測定及配合細胞療法產品使用的方法及組合物 | |
| TW202310745A (zh) | 實體腫瘤片段之冷凍保存方法 | |
| EP4522202A1 (en) | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist | |
| CN117940557A (zh) | 制备经修饰的肿瘤浸润性淋巴细胞的方法及其在过继性细胞治疗中的应用 | |
| WO2025101484A1 (en) | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies | |
| AU2024375198A1 (en) | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies | |
| JP2025537155A (ja) | Cd39/cd103選択に関連した腫瘍浸潤リンパ球(til)拡張のための方法 | |
| HK40112929A (zh) | 使用pd-1 talen基因敲低生成til产物的方法 | |
| HK40110554A (zh) | 制备经修饰的肿瘤浸润性淋巴细胞的方法及其在过继性细胞治疗中的应用 | |
| WO2023049862A1 (en) | Expansion processes and agents for tumor infiltrating lymphocytes | |
| HK40100826A (zh) | 使用肿瘤浸润性淋巴细胞疗法与ctla-4及pd-1抑制剂组合的治疗 | |
| CN118541159A (zh) | 使用pd-1 talen基因敲低生成til产物的方法 | |
| CN116829156A (zh) | 使用肿瘤浸润性淋巴细胞疗法与ctla-4及pd-1抑制剂组合的治疗 | |
| HK40107433A (zh) | 用於t细胞共培养物效力测定和配合细胞疗法产品使用的方法和组合物 |